1-20 of 75
Shuo Ma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Tanya Siddiqi, Jordan Gauthier, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Charalambos Andreadis, Daniel A. Ermann, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 4633.
https://doi.org/10.1182/blood-2024-200840
Published: 2024
Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Matthew J. Cortese, MD, MPH, Megan M Herr, Nisha Nair, Jason Romancik, Natalie Grover, Rahul S Bhansali, Colin Thomas, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, James A Davis, Christy Jesme, Ari Pelcovits, Megan Melody, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alex Niu, Alexey V. Danilov, Nirav N. Shah, Deborah M. Stephens, Jonathon B. Cohen, Leo I. Gordon, Stefan K. Barta, Narendranath Epperla, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 525.
https://doi.org/10.1182/blood-2024-212106
Published: 2024
Journal Articles

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Jacob D. Soumerai, Chan Y. Cheah, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, Wei Ding, Haiyi Guo, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2024-199175
Published: 2024
Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Natalie Grover, Jason T Romancik, Matthew J Cortese, Rahul S Bhansali, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alexey V. Danilov, Nirav N. Shah, Stefan K. Barta, Jonathon B Cohen, Leo I. Gordon, Deborah M. Stephens, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 612.
https://doi.org/10.1182/blood-2024-202665
Published: 2024
Journal Articles

Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Nitin Jain, Catherine C. Coombs, James D'Olimpio, Nirav N. Shah, Jacqueline C. Barrientos, Seung Tae Lee, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William G. Wierda, Varsha Gandhi, Javier Pinilla-Ibarz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1866.
https://doi.org/10.1182/blood-2024-208549
Published: 2024
Journal Articles

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Megan Melody, Natalie Grover, Stephanie Franco, Jason T Romancik, Matthew J Cortese, Tamara K Moyo, Rahul S Bhansali, Thomas Ollila, Vaishalee P Kenkre, Lindsey Fitzgerald, Brian Hess, Matthew Matasar, Geoffrey Shouse, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Shuo Ma, Jane N Winter, Adam Yuh Lin, Alexey Danilov, Ishan Roy, Stefan K. Barta, Leo I. Gordon, Deborah M. Stephens, Jonathon B Cohen, Narendranath Epperla, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 473.
https://doi.org/10.1182/blood-2024-201626
Published: 2024
Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

William G. Wierda, Kathleen Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J. Kipps, Peter A. Riedell, Herbert A. Eradat, Saad S. Kenderian, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Scott R. Solomon, Daniel A. Ermann, Jon E. Arnason, Abhinav Deol, Tatyana Feldman, Charalambos Andreadis, Monalisa Ghosh, Shuo Ma, Stephen J. Schuster, Usama Gergis, Julie M. Vose, Jacob D. Soumerai, Koen van Besien, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, Tanya Siddiqi
Journal: Blood
Blood (2024) 144 (Supplement 1): 887.
https://doi.org/10.1182/blood-2024-200339
Published: 2024
Journal Articles

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Nirav N. Shah, Zulfa Omer, Graham P. Collins, Francesco Forconi, Alexey Danilov, John C. Byrd, Dima El-Sharkawi, Emma Searle, Alvaro J Alencar, Shuo Ma, Sarah Injac, Talha Munir
Journal: Blood
Blood (2024) 144 (Supplement 1): 884.
https://doi.org/10.1182/blood-2024-194839
Published: 2024
Journal Articles

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Yoon Cheah
Journal: Blood
Blood (2023) 142 (Supplement 1): 327.
https://doi.org/10.1182/blood-2023-179541
Published: 2023
Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Benoit Tessoulin, Nirav N. Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C. Coombs, Ian W. Flinn, Manish Patel, Sunita D. Nasta, Jonathon B. Cohen, Alvaro J. Alencar, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Osterborg, Koji Izutsu, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Amy S. Ruppert, Wojciech Jurczak, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 325.
https://doi.org/10.1182/blood-2023-185852
Published: 2023
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Krish Patel, Julie M. Vose, Sunita D. Nasta, Jennifer R. Brown, Kami J. Maddocks, Jennifer A. Woyach, Nirav N. Shah, Bita Fakhri, Benoit Tessoulin, Shuo Ma, Deepa Jagadeesh, Ewa Lech-Maranda, Catherine C. Coombs, Manish Patel, Joanna M. Rhodes, Chaitra S Ujjani, Marc S. Hoffmann, Chan Y Cheah, Talha Munir, David Lewis, Lydia Scarfo, Toby A. Eyre, Alvaro J. Alencar, Jonathon B. Cohen, Andrew D. Zelenetz, Donald E. Tsai, Mei Li, Faith Bian, Paolo Abada, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1660.
https://doi.org/10.1182/blood-2023-180048
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Tanya Siddiqi, David G Maloney, Saad S. Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 330.
https://doi.org/10.1182/blood-2023-179529
Published: 2023
Journal Articles

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Catherine C. Coombs, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Ian W. Flinn, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Koji Izutsu, Wojciech Jurczak, William G. Wierda, Angely Loubert, Nalin Payakachat, Lisa M. Hess, Paolo Abada, Nicole Lamanna
Journal: Blood
Blood (2023) 142 (Supplement 1): 6535.
https://doi.org/10.1182/blood-2023-186145
Published: 2023
Journal Articles

Engraftment Syndrome Incidence after Immune Checkpoint Inhibitor Therapy in Pts with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Single Institutional Review

Oluwatobi Odetola, Kehinde Adekola, Jonathan Moreira, Reem Karmali, Shuo Ma, Kenneth R. Carson, Jayesh Mehta, Jane N. Winter, Leo I. Gordon, Adam Yuh Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 7060.
https://doi.org/10.1182/blood-2023-185289
Published: 2023
Journal Articles

A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in High-Risk DLBCL

Oluwatobi Odetola, Shuo Ma, Jane N. Winter, Barbara Pro, Ishan Roy, Ping Xie, Bin Zhang, George Koulogeorgas, Xinlei Mi, Robert Bayer, Robert Eisner, Valerie Nelson, Habib Shaikh, Dean Tsarwhas, Faisal Saghir, Parameswaran Venugopal, Leo I. Gordon, Reem Karmali
Journal: Blood
Blood (2023) 142 (Supplement 1): 4462.
https://doi.org/10.1182/blood-2023-185065
Published: 2023
Journal Articles

Live Lymphoma and CLL Cells inside the Bone Marrow Fibroblasts: Implication in Residual Disease Persistence

Y. Lynn Wang, Carrie Frazen, Andrey Efimov, Priyal Patel, Pin Lu, Shuo Ma, Katherine Amira Carrol, Edna Cukierman, Marcus R. Messmer, Janusz Franco-Barraza, Juehua Gao, Aldana Vistarop
Journal: Blood
Blood (2023) 142 (Supplement 1): 6506.
https://doi.org/10.1182/blood-2023-179994
Published: 2023
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Pier Luigi Zinzani, Michael L. Wang, Sunita D. Nasta, Ewa Lech-Maranda, Yoshiaki Ogawa, Bita Fakhri, Bryone Kuss, Kaname Miyashita, Krish Patel, Catherine C. Coombs, Shuo Ma, Manish Patel, Minal A. Barve, Benoit Tessoulin, Anastasios Stathis, Won Seog Kim, Daisuke Ennishi, Daigo Hashimoto, Kensuke Kojima, Andrew D. Zelenetz, Jonathon B. Cohen, Julie M. Vose, Kami J. Maddocks, Talha Munir, Fangfang Sun, Faith Bian, Donald E. Tsai, Paolo Abada, Chan Y. Cheah
Journal: Blood
Blood (2023) 142 (Supplement 1): 3026.
https://doi.org/10.1182/blood-2023-181309
Published: 2023
Journal Articles

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Megan Melody, Narendranath Epperla, Geoffrey P. Shouse, Jason T. Romancik, Tamara K. Moyo, Vaishalee P Kenkre, Thomas Ollila, Lindsey Fitzgerald, Brian Hess, Kevin A. David, Kaitlin Annunzio, Megan Herr, Rahul S. Bhansali, Elyse I Harris, James A Davis, Oluwatobi Odetola, Adam Yuh Lin, Jonathan Moreira, Shuo Ma, Jane N. Winter, Deborah M. Stephens, Alexey Danilov, Nirav N. Shah, Ishan Roy, Stefan K. Barta, Matthew J Cortese, Pallawi Torka, Jonathon B. Cohen, Leo I. Gordon, Reem Karmali
Journal: Blood
Blood (2023) 142 (Supplement 1): 1738.
https://doi.org/10.1182/blood-2023-183011
Published: 2023
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Jonathon B. Cohen, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y. Cheah, Toby A. Eyre, Chaitra S Ujjani, Youngil Koh, Won Seog Kim, Sunita D. Nasta, Ian W. Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J. Alencar, David Lewis, Jennifer A. Woyach, Kami J. Maddocks, Krish Patel, Yucai Wang, Joanna M. Rhodes, Constantine S. Tam, John F. Seymour, Hirokazu Nagai, Julie M. Vose, Bita Fakhri, Marc S. Hoffmann, Francisco J. Hernandez-Ilizaliturri, Andrew D. Zelenetz, Anita Kumar, Talha Munir, Donald E. Tsai, Minna Balbas, Bin Liu, Amy S. Ruppert, Bastien Nguyen, Lindsey E. Roeker, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 981.
https://doi.org/10.1182/blood-2023-181627
Published: 2023
Journal Articles

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nitin Jain, James D'Olimpio, Andew gillis-Smith, Seung Tae Lee, Nirav N. Shah, Javier Pinilla-Ibarz, Catherine C. Coombs, Jacqueline C. Barrientos, Shuo Ma, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3288.
https://doi.org/10.1182/blood-2023-182568
Published: 2023